AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00639652 — intervention group
Intervention type: PROCEDURE
Intervention: 3D-histology
Description: The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
Study NCT00639652 — intervention group
Intervention type: PROCEDURE
Intervention: Shave excision
Description: Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
Study NCT00319267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
Study NCT04698577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training
Description: The training was delivered face-to-face in groups of three participants. Participants were involved in a game of table tennis with two players and one spectator. The roles were rotated every 5 minutes so that each participant experienced 10 minutes of play and 5 minutes of observation. The game was played as normal with one point awarded to the player for every score achieved. All 3 players were asked to keep the score of the game in their minds during each 5-minute round. Participants had two objectives 1) to play and win the game and 2) to silently keep the score of the game. The researcher watched the game and accurately kept score, using a notepad. At the end of every 5-minute round, the researcher paused play and asked each child to write down the score they were holding in their mind. The researcher then revealed the true score, asked participants to swap roles and commence another round.
Study NCT04698577 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The control group was the same as the training group except for the core training mechanism; children were not required to mentally keep score. The researcher kept score by continually calling out the updated score as each point was won. The observing child was simply told to wait his/her turn.
Study NCT02702297 — intervention group
Intervention type: OTHER
Intervention: single arm
Description: Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
Study NCT05616689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled hyperpolypharmacy
Description: Bundled hyperpolypharmacy playbook to be used by pharmacist, with physician approval, in shared decision making with participant,
Study NCT02929043 — intervention group
Intervention type: OTHER
Intervention: air puffs
Study NCT01957956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
Description: Given ID
Study NCT01957956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02867631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
Description: 6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
Study NCT00962715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine Trivalent Inactivated (TIV)
Description: 15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
Study NCT00962715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEGrIFN-α, Pegasys)
Description: 180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
Study NCT00962715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon (IFNα, Roferon-A)
Description: 3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
Study NCT04680650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia was maintained with sevoflurane
Description: After endotracheal intubation, anesthesia was maintained with 1.5-3% sevoflurane, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DS.
Study NCT04680650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia was maintained with propofol
Description: After endotracheal intubation, anesthesia was maintained with 2-4 μg/mL target-controlled infusion of propofol, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DP.
Study NCT03931018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.
Study NCT02769598 — intervention group
Intervention type: DEVICE
Intervention: ANI Index for Hospitalized children
Description: Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
Study NCT01390545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Veltuzumab
Description: administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
Study NCT01390545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Veltuzumab
Description: administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
Study NCT01026584 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: 6 week prospective study
Study NCT02093611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02093611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ATP
Description: 400 mg of ATP
Study NCT00628186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external drainage tube [polyethylene pancreatic drainage tube]
Description: External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
Study NCT00628186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal drainage tube [polyethylene pancreatic drainage tube]
Description: Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
Study NCT04340219 — intervention group
Intervention type: OTHER
Intervention: Survey administration
Description: Covid-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, WHO Quality of Life-BREF
Study NCT01263912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LCPUFA Supplement
Description: Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
Study NCT01263912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
Study NCT02848729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Acetaminophen
Description: Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
Study NCT01854047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICS/LABA therapy
Description: Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
Study NCT01854047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/albuterol
Description: Oral inhalation as needed
Study NCT01854047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol/albuterol
Description: Oral inhalation as needed
Study NCT02848729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)
Study NCT02848729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Morphine
Description: Morphine for IV administration (0.125 mg/kg)
Study NCT02848729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: Placebo tablets matching oral acetaminophen
Study NCT02848729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline placebo matching IV acetaminophen
Study NCT01998984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ingenol mebutate
Study NCT01854047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosalbutamol/levalbuterol
Description: Oral inhalation as needed
Study NCT01998984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01998984 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01126047 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: eCO testing
Description: exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
Study NCT00361413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept (AMEVIVE®)
Description: Alefacept
Study NCT00361413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: these patients will receive the same treatment as group A, without alefacept
Study NCT01854047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levosalbutamol/levalbuterol
Description: Oral inhalation as needed
Study NCT00076622 — intervention group
Intervention type: DRUG
Intervention: Antidepressant medication
Description: Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
Study NCT00076622 — intervention group
Intervention type: DRUG
Intervention: No antidepressant medication
Description: Participants assigned to discontinue current medication (no antidepressant medication) will be monitored over a period of one year for recurrence of depression and related symptoms.
Study NCT04140318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Sintilimab 200mg, iv, 30-60min, q3w;
Study NCT03553394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Acetate
Description: Will receive a fluid bolus immediately (Ringer's Acetate 5 mls/kg bw) if oliguric/anuric for two consecutive hours
Study NCT04967131 — intervention group
Intervention type: OTHER
Intervention: PNF exercises
Description: PNF exercises were applied in 3 sets of 15 repetitions based on movement in the diagonal plane, using head, neck and chin patterns. Contractions were sustained for at least 10 seconds.
Study NCT03464669 — intervention group
Intervention type: OTHER
Intervention: Prenatal education
Description: Observational study : natural distribution of participants between groups
Study NCT01903941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Study NCT01903941 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Only Counseling
Study NCT02604264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClearGuard HD end cap
Description: The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub
Study NCT03696472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic assisted surgery
Description: robotic assisted surgery was benefit to operation
Study NCT03696472 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic
Description: conventional laparoscopic surgery
Study NCT02050178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-54F28, Nab-Paclitaxel and Gemcitabine
Study NCT04810728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extract Psidii guava
Description: 2 Capsule Extract Psidii guava, three times daily
Study NCT04810728 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard therapy for Covid-19 patient
Description: (Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
Study NCT04810728 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy for Covid-19 patient
Description: (Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
Study NCT01162798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infant formula
Description: test infant formula fed to infants until 6 months corrected gestational age
Study NCT01162798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control infant formula
Description: commercially available infant formula
Study NCT01604278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237 50 µg and indacaterol 150 µg
Description: NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
Study NCT01604278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to NVA237 and indacaterol 150 µg
Description: Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
Study NCT02565134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.1%
Description: Topical application
Study NCT02565134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.3%
Description: Topical application
Study NCT02565134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: Topical application
Study NCT02565134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream vehicle
Description: Topical application
Study NCT02793856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: To deplete Tregs before collecting peripheral blood
Study NCT02793856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
Study NCT03680742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Neurovascular System
Description: The Contour Neurovascular System™ is an intrasaccular, self-expanding, embolization device intended for the treatment of unruptured intracranial aneurysms.
Study NCT02298335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
Study NCT01282970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 135585
Description: oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
Study NCT01282970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 135585
Description: oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
Study NCT00693862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa, carbidopa, entacapone
Study NCT00693862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa, carbidopa
Study NCT01701752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1 + Placebo
Study NCT01701752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1 + TIV
Study NCT01701752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1-Adjuvant + Placebo
Study NCT01701752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1-Adjuvant + TIV
Study NCT01701752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant + TIV
Study NCT01701752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + TIV
Study NCT01701752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1
Study NCT01701752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP-01.1-Adjuvant
Study NCT01701752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00773227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous myoblasts transplantation and myotomy
Description: Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
Study NCT03089762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of SVF plus PRP
Description: administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
Study NCT00167297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Study NCT00395057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 211745
Description: AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
Study NCT00395057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 211745
Description: AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
Study NCT00395057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 211745
Description: AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
Study NCT00395057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 500µg
Description: Ranibizumab 500µg injections at Day 1, Month 1, Month 2
Study NCT03086564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADCC & TACE
Description: Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2\*10\^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.
Study NCT03086564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE solely in the first day of a clinical course.
Study NCT04140318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w
Study NCT02096783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: informational intervention
Description: Given scripted intervention
Study NCT02096783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling intervention
Description: Given standard counseling
Study NCT02096783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Given standard counseling
Study NCT02096783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02096783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03352245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescribed Activity
Description: Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)
Study NCT02737865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Sonazoid: Commercially available contrast material for ultrasonography
Study NCT02737865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superb-Microvascular imaging
Description: Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
Study NCT01559103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5117
Description: Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg
Study NCT01559103 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MEDI5117 Placebo
Description: Intravenous infusion administered over 60 minutes
Study NCT02835430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap and PRF with DFDBA
Description: • For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
Study NCT02835430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap and PRF without DFDBA
Description: . For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.